DEF: BiomX Seeks Stockholder Approval for Warrant Exercise to Comply with NYSE American Listing Rules

BiomX Inc. is holding a special meeting to seek stockholder approval for the exercise of certain warrants into common stock to comply with NYSE American listing rules.

Summary

• BiomX Inc. is convening a Special Meeting of Stockholders on April 21, 2025, to vote on two proposals.
• The primary proposal (Proposal No. 1) seeks approval for the exercise of certain warrants into shares of common stock, as required by NYSE American LLC Listed Company Guide Section 713.
• These warrants were previously issued in private placements on February 25, 2025, under a Securities Purchase Agreement and an Inducement Letter.
• Approval is needed because the exercise of these warrants would result in the issuance of 20% or more of BiomX's outstanding shares.
• The second proposal (Proposal No. 2) concerns the adjournment or postponement of the Special Meeting, if necessary, to continue soliciting votes for Proposal No. 1.
• The Board of Directors recommends voting FOR both proposals.
• Stockholders of record as of March 17, 2025, are eligible to vote.
• As of March 17, 2025, there were 24,966,053 shares of Common Stock outstanding and entitled to vote.
• 14,773,500 shares of Series X Preferred Stock were outstanding as of March 17, 2025, none of which are entitled to vote with respect to any matters to be acted upon at the Special Meeting.

Sentiment

Score: 6

Explanation: The document is primarily procedural, seeking approval for a warrant exercise. While there is potential dilution for existing shareholders, the overall tone is neutral and focused on compliance.

Positives

• Approval of the proposal would allow BiomX to proceed with the exercise of warrants, potentially providing the company with additional capital.
• The Board believes the proposals are in the best interests of BiomX's stockholders.

Negatives

• Approval of the warrant exercise will result in significant dilution for existing stockholders.
• If the proposal is not approved, BiomX is obligated to continue soliciting votes, potentially incurring additional expenses.

Risks

• Failure to obtain stockholder approval would prevent the exercise of the warrants.
• The sale into the public market of the underlying Common Stock could materially and adversely affect the market price of our Common Stock.
• Existing stockholders will immediately experience significant dilution if the stockholders approve this proposal.

Future Outlook

The company will continue to solicit stockholder approval for the warrant exercise, potentially holding additional special meetings if necessary.

Management Comments

• Jonathan Solomon, Chief Executive Officer, urges stockholders to read the proxy statement and vote as soon as possible.
• The Board has determined that the proposals are advisable, fair and in the best interests of BiomX's stockholders.

Industry Context

The requirement for stockholder approval for issuances exceeding 20% of outstanding shares is a standard governance practice under NYSE American listing rules.

Comparison to Industry Standards

• Many companies listed on exchanges like NYSE American are subject to similar rules requiring stockholder approval for significant share issuances.
• This ensures that existing shareholders have a say in decisions that could materially dilute their ownership.

Stakeholder Impact

• Approval of the warrant exercise will dilute the ownership of existing shareholders.
• Failure to approve the proposal could hinder the company's ability to raise capital.

Next Steps

• Stockholders to vote on the proposals before the Special Meeting on April 21, 2025.
• The company will announce the voting results in a Current Report on Form 8-K within four business days following the Special Meeting.

Key Dates

Keywords

warrants, stockholder approval, NYSE American, issuance, common stock, BiomX